Overview

Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)

Status:
Completed
Trial end date:
2021-08-16
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.
Phase:
Phase 2
Details
Lead Sponsor:
EMD Serono Research & Development Institute, Inc.
Collaborator:
Merck KGaA, Darmstadt, Germany